Genmab Reports Record Sales of DARZALEX for Q3 Performance

Author: Dylan Bailey Updated: 10-14-2025 06:30 AM

Genmab's Third Quarter Sales Performance

In an exciting announcement, Genmab A/S has revealed its outstanding net sales for DARZALEX (daratumumab) in the third quarter of 2025, reaching a staggering USD 3,672 million. This achievement underscores the growing impact of their biopharmaceutical advancements on the global market.

Sales Breakdown and Revenue Generation

The net trade sales for DARZALEX reflect an impressive USD 2,088 million generated from the U.S. market, while the rest of the world contributed USD 1,584 million. These figures highlight the strong demand and acceptance for DARZALEX across various regions, demonstrating Genmab's strategic collaboration with Johnson & Johnson (J&J) in the commercialization of this therapeutic.

Royalties from J&J

Genmab has established a solid partnership with Johnson & Johnson, allowing the company to receive royalties on the worldwide sales of DARZALEX. This licensing agreement empowers Genmab to benefit from both the intravenous and subcutaneous forms of daratumumab, further enhancing their revenue stream.

Innovative Biopharmaceutical Solutions

For over two decades, Genmab has remained dedicated to improving patient outcomes through cutting-edge antibody therapeutics. With an innovative approach, the company has cultivated a strong pipeline that includes next-generation technology platforms, positioning itself favorably in the biotechnology landscape.

Commitment to Oncology

Genmab's vision by 2030 is to revolutionize cancer treatment through their proprietary antibody medicines. With a mission to create therapies that truly enhance patient lives, their forward-thinking strategies ensure that they are at the forefront of biopharmaceutical innovation.

Global Presence and Impact

Headquartered in Copenhagen, with a strong international presence, Genmab continues to expand its reach across North America, Europe, and the Asia Pacific regions. Their commitment to healthcare innovation not only makes a difference in the lives of patients facing serious diseases but also solidifies their reputation within the biotechnology community.

Contact Information

For further inquiries, Genmab encourages communication through their team. Marisol Peron serves as the Senior Vice President for Global Communications and Corporate Affairs, reachable at +1 609 524 0065 or via email at mmp@genmab.com. Additionally, Andrew Carlsen, Vice President and Head of Investor Relations, can be contacted at +45 3377 9558 or acn@genmab.com.

Frequently Asked Questions

What is DARZALEX?

DARZALEX (daratumumab) is a monoclonal antibody used for the treatment of multiple myeloma, a type of blood cancer.

How much did Genmab earn from DARZALEX in Q3 2025?

In the third quarter of 2025, Genmab reported net sales of USD 3,672 million for DARZALEX.

Who is Genmab's partner in the development of DARZALEX?

Genmab collaborates with Johnson & Johnson for the development and commercialization of DARZALEX.

What is Genmab's vision for 2030?

Genmab aims to transform the lives of patients with cancer through innovative antibody therapies by 2030.

Where is Genmab headquartered?

Genmab is headquartered in Copenhagen, Denmark, with a presence in North America, Europe, and the Asia Pacific.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.